Search results for "Performance status"

showing 10 items of 146 documents

Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib

2015

Treatment with sorafenib of patients with advanced hepatocellular carcinoma is challenged by anticipated discontinuation due to tumor progression, liver decompensation, or adverse effects. While postprogression survival is clearly determined by the pattern of tumor progression, understanding the factors that drive prognosis in patients who discontinued sorafenib for any reason may help to improve patient management and second-line trial design. Patients consecutively admitted to three referral centers who were receiving best supportive care following permanent discontinuation of sorafenib for any reason were included. Postsorafenib survival (PSS) was calculated from the last day of treatmen…

MalePredictive Value of TestGastroenterologyCohort StudiesAntineoplastic AgentProspective StudiesProspective cohort studyMultivariate AnalysiLiver NeoplasmsHepatitis CMiddle AgedSorafenibItalyLiver NeoplasmHepatocellular carcinomaFemaleSurvival Analysimedicine.drugHumanSorafenibNiacinamidePhenylurea Compoundmedicine.medical_specialtyCarcinoma HepatocellularDrug-Related Side Effects and Adverse ReactionsSettore MED/12 - GASTROENTEROLOGIAReproducibility of ResultAntineoplastic AgentsRisk AssessmentPredictive Value of TestsInternal medicinemedicineHumansNeoplasm InvasivenessSurvival analysisAgedNeoplasm StagingNeoplasm InvasiveneAnalysis of VarianceHepatologyPerformance statusbusiness.industryPhenylurea CompoundsPatient SelectionCarcinomaSettore MED/09 - MEDICINA INTERNAReproducibility of ResultsHepatocellularHepatologymedicine.diseaseSurvival AnalysisSurgeryDiscontinuationProspective StudieWithholding TreatmentMultivariate AnalysisCohort StudiebusinessDrug-Related Side Effects and Adverse Reaction
researchProduct

Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation

2019

Regorafenib is one option for second-line treatment of hepatocellular carcinoma (HCC), improving overall survival (OS) of sorafenib-tolerant patients who develop progression. We aim to evaluate the safety and outcomes of regorafenib as second-line treatment for HCC recurrence after liver transplantation (LT). This is a retrospective, multicenter, international study including regorafenib-treated LT patients (2015-2018), with analysis of baseline characteristics and evolutionary events during sorafenib/regorafenib treatment. Twenty-eight LT patients (57 years, 7% cirrhotics, 54% performance status 1) were included. Median time from LT to regorafenib initiation was 3.9 (1.1-18.5) years; media…

MalePyridinesmedicine.medical_treatment030230 surgeryLiver transplantationchemotherapyGastroenterologychemistry.chemical_compound0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsImmunology and AllergyPharmacology (medical)Liver NeoplasmsMiddle AgedSorafenibPrognosisRecurrent Hepatocellular Carcinomaside effectsHepatocellular carcinomaFemalemedicine.drugSorafenibAdultmedicine.medical_specialtyCarcinoma Hepatocellularcancer/malignancy/neoplasiaclinical research/practice03 medical and health sciencesYoung AdultInternal medicineRegorafenibmedicineHumansAdverse effectAgedRetrospective StudiesTransplantationdrug interactionPerformance statusbusiness.industryPhenylurea Compoundsmedicine.diseaseDiscontinuationLiver TransplantationchemistryDrug Resistance NeoplasmNeoplasm Recurrence Localpharmacologybusinessliver transplantation/hepatologyFollow-Up Studies
researchProduct

Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy

2016

AIM To study the tolerance and the efficiency of FOLFIRINOX in elderly patients diagnosed with colorectal or pancreatic cancer. METHODS This retrospective study included elderly patients aged over 70 years of age treated at Georges-Francois Leclerc Center by FOLFIRINOX for histological proved colorectal or pancreatic cancer between January 2009 and January 2015. Chemotheapy regimen consisted of oxaliplatin (85 mg/m(2) in over 120 min) followed by leucovorin (400 mg/m(2) in over 120 min), with the addition, after 30 min of irinotecan (180 mg/m(2) in over 90 min) then 5 fluorouracil (5FU) (400 mg/m(2) administred intravenous bolus), followed by 5FU (2400 mg/m2 intraveinous infusion over 46 h)…

MaleTime FactorsOrganoplatinum CompoundsColorectal cancerFOLFIRINOXLeucovorinPooled AnalysisInternational-SocietyKaplan-Meier EstimateOlder PatientsGastroenterology0302 clinical medicineRisk FactorsAntineoplastic Combined Chemotherapy Protocols030212 general & internal medicineAged 80 and overAge FactorsGastroenterologyCommon Terminology Criteria for Adverse EventsGeneral Medicine3. Good healthOxaliplatinTreatment Outcome030220 oncology & carcinogenesisDisease ProgressionFolfirinoxFemale[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyFluorouracilFranceFolfirinox RegimenColorectal Neoplasmsmedicine.drugmedicine.medical_specialtyOxaliplatin FolfirinoxIrinotecanDisease-Free SurvivalDrug Administration Schedule03 medical and health sciencesPancreatic CancerRetrospective StudyInternal medicinePancreatic cancermedicineHumansChemotherapyGeriatric AssessmentAgedRetrospective StudiesColorectal CancerChi-Square DistributionPerformance statusbusiness.industry[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyElderly Patientsmedicine.diseasePhase-Ii Trial1st-Line TreatmentSurgeryPancreatic NeoplasmsIrinotecanRegimenMultivariate AnalysisCamptothecinOpen-LabelFeasibility TreatmentTomography X-Ray Computedbusiness
researchProduct

Associations between sex, age and spiritual well-being scores on the EORTC QLQ-SWB32 for patients receiving palliative care for cancer: A further ana…

2019

Objective: The EORTC QOL Group has recently completed the cross-cultural development and validation of a standalone measure of spiritual well-being (SWB) for cancer patients receiving palliative care: the EORTC QLQ-SWB32. The measure includes four scales: Relationships with Others, Relationship with Self, Relationship with Someone or Something Greater, and Existential, plus a Global-SWB item. This paper reports on further research investigating relationships between sex, age and SWB for patients receiving palliative care for cancer—adjusting for other socio-demographic, clinical and function variables, including WHO performance status and EORTC QLQ-C15-PAL emotional and physical function sc…

MaleValidation studyPalliative careExistentialismEmotionsEmotional functioningPhysical function03 medical and health sciences0302 clinical medicineSex FactorsNeoplasmsSurveys and QuestionnairesMedicineHumansInterpersonal RelationsSpiritualityAgedPerformance statusbusiness.industryPalliative CareAge FactorsCancerMiddle Agedmedicine.diseaseSelf ConcepthumanitiesCross-Sectional StudiesOncologySocioeconomic FactorsVDP::Medisinske Fag: 700::Helsefag: 800030220 oncology & carcinogenesisWell-beingMultivariate AnalysisQuality of LifeFemaleIncurable cancerbusinessClinical psychologyEuropean Journal of Cancer Care
researchProduct

Barriers and Adherence to Pain Management in Advanced Cancer Patients

2020

Aim To assess patients' barriers to pain management and analgesic medication adherence in patients with advanced cancer. Methods This was a prospective cross-sectional study in patients with advanced cancer receiving chronic opioid therapy. Age, gender, cancer diagnosis, Karnofsky level, and educational status were recorded. The Brief Pain Inventory (BPI), Edmonton Symptom Assessment Scale (ESAS), Memorial Delirium Assessment Scale (MDAS), Barriers Questionnaire II (BQ-II), Medication Adherence Rating Scale (MARS), and Hospital Anxiety and Depression Scale (HADS) were the measurement instruments used. Results One-hundred-thirteen patients were analyzed. The mean age was 68 (±13) years, and …

Malecancer painmedicine.medical_specialtyadherence to medicationPalliative careAnalgesicSettore MED/42 - Igiene Generale E ApplicataHospital Anxiety and Depression ScaleHealth Services Accessibility03 medical and health sciences0302 clinical medicine030202 anesthesiologyRating scaleNeoplasmsmedicineHumansPain ManagementProspective StudiesKarnofsky Performance StatusBrief Pain InventoryDepression (differential diagnoses)Agedpalliative carebusiness.industryCross-Sectional StudiesAnesthesiology and Pain MedicineopioidPhysical therapyPatient CompliancebarrierDeliriumFemalemedicine.symptombusinessCancer pain030217 neurology & neurosurgeryPain Practice
researchProduct

Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre s…

2015

Background & Aims The role of hepatic resection for hepatocellular carcinoma (HCC) in different Barcelona Clinic Liver Cancer (BCLC) stages is controversial. We aimed at measuring the survival benefit of resection vs. non-surgical-therapies in each BCLC stage. Methods Using the ITA.LI.CA database, we identified 2090 BCLC A, B, and C HCC patients observed between 2000 and 2012: 550 underwent resection, 1046 loco-regional therapy (LRT), and 494 best supportive care (BSC). A multivariate log-logistic model was chosen to predict median survival (MS) after resection vs. MS after LRT or BSC. The results were expressed as net survival benefit of resection: (MS resection - MS LRT)/MS BSC. Resul…

Malemedicine.medical_specialtyCirrhosisCarcinoma HepatocellularLoco-regional therapieHepatocellular carcinomaSettore MED/12 - GASTROENTEROLOGIAHepatitis C virusKaplan-Meier Estimatemedicine.disease_causeGastroenterologyCohort StudiesLiver diseaseInterquartile rangeInternal medicinemedicineHumansBest supportive care; Cirrhosis; Hepatocellular carcinoma; Liver resection; Loco-regional therapies; Survival benefit; Aged; Carcinoma Hepatocellular; Cohort Studies; Female; Humans; Italy; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prognosis; Treatment Outcome; Medicine (all); HepatologyBEST SUPPORTING CAREAgedNeoplasm StagingCirrhosiHepatologyPerformance statusLiver resectionbusiness.industryMedicine (all)CIRRHOISISCarcinomaLiver NeoplasmsHepatocellularMiddle Agedmedicine.diseasePrognosisBCLC StageTreatment OutcomeCirrhosisItalySurvival benefitHepatocellular carcinomaMultivariate AnalysisFemaleLoco-regional therapiesLiver cancerbusinessBest supportive careJournal of hepatology
researchProduct

Emergencies in patients with advanced cancer followed at home.

2012

Abstract CONTEXT: Patients with advanced cancer stay at home for most of their time, and acute problems may occur during home care. Caregivers may call medical services for an emergency, which can result in patients being admitted to the hospital. No data exist on emergencies in patients followed by a home care team. OBJECTIVES: The aim of this multicenter prospective study was to assess the frequency, reasons for, and subsequent course of emergency calls for patients followed at home by a palliative care team. METHODS: A consecutive sample of patients admitted to home care programs was surveyed for a period of seven months. Epidemiological data, and characteristics of emergency calls and o…

Malemedicine.medical_specialtyEmergency Medical ServicesPalliative careMEDLINEContext (language use)Settore MED/42 - Igiene Generale E Applicataadvanced cancer; home care; epidemiologic studypalliative care emergencyNeoplasmsEpidemiologymedicineEmergency medical servicesadvanced cancerHumansIn patientProspective StudiesKarnofsky Performance StatusProspective cohort studyNursing (all)2901 Nursing (miscellaneous)General NursingAgedpalliative carebusiness.industryemergency medical caremedicine.diseaseHome Care ServicesTelephoneAnesthesiology and Pain Medicineemergency medical care; Home care; palliative care; palliative care emergency; Aged; Caregivers; Emergency Medical Services; Female; Home Care Services; Humans; Italy; Karnofsky Performance Status; Male; Neoplasms; Prospective Studies; Telephone; Emergencies; Anesthesiology and Pain Medicine; Neurology (clinical); Nursing (all)2901 Nursing (miscellaneous)CaregiversItalyepidemiologic studyEmergency medicineDeliriumFemaleNeurology (clinical)Medical emergencymedicine.symptomEmergencieshome carebusinessJournal of pain and symptom management
researchProduct

Delirium assessed by Memorial Delirium Assessment Scale in advanced cancer patients admitted to an acute palliative/supportive care unit

2017

Background: Delirium is often unrecognized in cancer patients. The aim of this study was to investigate the prevalence of delirium assessed by the Memorial Delirium Assessment Scale (MDAS) and possible associated factors on admission to an acute palliative/supportive care unit (APSCU). The secondary outcome was to assess changes in MDAS and symptom burden at time of discharge. Methods: A consecutive sample of advanced cancer patients who were admitted to an APSCU was prospectively assessed for a period of 10 months. Patient demographics, including age, gender, primary diagnosis, Karnofsky status, stage of disease, and educational level were collected. The Edmonton Symptom Assessment Scale (…

Malemedicine.medical_specialtyPalliative careDiseaseCONSECUTIVE SAMPLE03 medical and health sciences0302 clinical medicineNeoplasmsAdvanced cancerparasitic diseasesmedicinePrevalenceHumans030212 general & internal medicineKarnofsky Performance StatusStage (cooking)Intensive care medicineReferral and ConsultationAgedAged 80 and overpalliative carebusiness.industryMedicine (all)edmonton symptom assessment scaleCancerDeliriummemorial delirium assessment scaleGeneral MedicineAssessment scaleLength of StayMiddle Agedmedicine.diseaseAdvanced cancerPatient DischargeHospitalization030220 oncology & carcinogenesisEmergency medicineDeliriumNeoplasmFemaleKarnofsky Performance Statumedicine.symptombusinessHuman
researchProduct

The course of symptom frequency and intensity in advanced cancer patients followed at home

2000

Four hundred consecutive patients who were referred to a home palliative care program were prospectively surveyed to estimate the prevalence and severity of common symptoms according to the changes in the performance status. Patients were admitted for the presence of different symptoms and psychosocial support. Common symptoms included in a standard form were rated for severity (absent 0, mild 1, moderate 2, severe 3) for each visit. Pain intensity was rated on a numerical scale (0-10). For each level of Karnofsky performance score (K), the frequency and the worse symptom intensity were recorded until patient's death. Data from 370 patients were analyzed. Pain was effectively controlled. In…

Malemedicine.medical_specialtyPalliative careNauseaEpidemiologyPopulationSymptomPainNeoplasmsInternal medicinemedicineHumansProspective StudiesProspective cohort studyeducationGeneral NursingNursing (all)2901 Nursing (miscellaneous)AgedPain MeasurementCancereducation.field_of_studyPerformance statusbiologybusiness.industryMiddle Agedbiology.organism_classificationHome Care ServicesDysphagiaAnesthesiology and Pain MedicineNeurologyPyrosisVomitingPhysical therapyKarnofsky performance statuPalliative careFemaleNeurology (clinical)medicine.symptombusiness
researchProduct

The frequency of alcoholism in patients with advanced cancer admitted to an acute palliative care unit and a home care program

2015

Abstract Context Cancer patients with a history of alcoholism may be problematic. The frequency of alcoholism among patients with advanced cancer has never been reported in Italy or other European countries. Objectives The aim of this prospective study was to determine the frequency of alcoholism, assessed with a simple and validated instrument, among patients with advanced cancer who were referred to two different palliative care settings: an acute inpatient palliative care unit (PCU) of a comprehensive cancer center in a metropolitan area and a home care program (HCP) in a territorial district, localized in the mountains of Italy. Methods A consecutive sample of patients admitted to an in…

Malemedicine.medical_specialtyPediatricsPalliative careContext (language use)advanced cancer patientsNursingCancer Care Facilitiesadvanced cancer patients; Alcoholism; CAGE; palliative care; Anesthesiology and Pain Medicine; NursingSettore MED/42 - Igiene Generale E ApplicataInterviews as Topicadvanced cancer patientSex FactorsNeoplasmsSurveys and QuestionnairesmedicineHumansIn patientProspective StudiesKarnofsky Performance StatusPsychiatryProspective cohort studyGeneral NursingNursing (all)2901 Nursing (miscellaneous)Agedpalliative carePerformance statusbusiness.industryMedicine (all)Age FactorsCanceradvanced cancer patients; Alcoholism; CAGE; palliative care; Age Factors; Aged; Alcoholism; Female; Humans; Interviews as Topic; Italy; Karnofsky Performance Status; Male; Middle Aged; Neoplasms; Palliative Care; Prospective Studies; Sex Factors; Surveys and Questionnaires; Cancer Care Facilities; Home Care Services; Anesthesiology and Pain Medicine; Neurology (clinical); Nursing (all)2901 Nursing (miscellaneous); Medicine (all)Cancer Care FacilitiesMiddle Agedmedicine.diseaseHome Care ServicesAlcoholismAnesthesiology and Pain MedicineItalyCAGEFemaleNeurology (clinical)Care programbusiness
researchProduct